Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

• Published in: Haematologica (Roma) Vol. 100; no. 9; pp. 1207 - 1213
• Main Authors: García-Sanz, Ramón, Oriol, Albert, Moreno, María J, de la Rubia, Javier, Payer, Angel R, Hernández, Miguel T, Palomera, Luis, Teruel, Ana I, Blanchard, María J, Gironella, Mercedes, Ribas, Paz, Bargay, Joan, Abellá, Eugenia, Granell, Miquel, Ocio, Enrique M, Ribera, Josep M, San Miguel, Jesús F, Mateos, María V
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01-09-2015
• Subjects: Adult; Aged; Bone Diseases - drug therapy; Bone Diseases - mortality; Bone Diseases - pathology; Diphosphonates - administration & dosage; Disease-Free Survival; Humans; Imidazoles - administration & dosage; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Multiple Myeloma - pathology; Survival Rate
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2015.128439

This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008.